Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.20 +0.70 (+1.51%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

40 41 Next >

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗

September 27, 2024

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Via Investor's Business Daily

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs ↗

September 25, 2024

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗

September 25, 2024

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...

Via Benzinga

Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

September 24, 2024

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

Via MarketBeat

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences ↗

September 23, 2024

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.

Via Benzinga

Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval ↗

September 23, 2024

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the...

Via Benzinga

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices ↗

September 20, 2024

FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...

Via Benzinga

Topics Lawsuit

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows ↗

September 20, 2024

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed...

Via Benzinga

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

September 20, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗

September 18, 2024

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...

Via Benzinga

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

September 13, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Should You Buy Novavax Stock After This Regulatory Win? ↗

September 13, 2024

The biotech continues to earn important wins, but is it enough?

Via The Motley Fool

Biotech Breakout: Stocks for Your Watchlist

September 12, 2024

The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.

Via MarketBeat

Topics ETFs

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease ↗

September 11, 2024

Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

Via Benzinga

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

September 11, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Despite its impressive fundamentals, NASDAQ:SNY remains undervalued. ↗

September 10, 2024

When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

Via Benzinga

Why Sanofi Stock Was Robustly Healthy Today ↗

September 03, 2024

Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.

Via The Motley Fool

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials ↗

September 03, 2024

Sanofi's phase 3 HERCULES study data shows tolebrutinib met the primary endpoint in delaying disability progression in non-relapsing secondary progressive multiple sclerosis.

Via Benzinga

European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday? ↗

September 02, 2024

Global markets started September cautiously, with thin trading volumes as U.S. stock markets were closed for the Labor Day holiday.

Via Benzinga

Topics Energy

Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates ↗

August 26, 2024

State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...

Via Benzinga

Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy? ↗

August 24, 2024

Don't be too quick to jump on the Wall Street bandwagon.

Via The Motley Fool

ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗

August 20, 2024

"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...

Via Benzinga

Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell? ↗

August 19, 2024

Its 12-month relative strength performance is impressive, but Novavax now faces resistance.

Via Investor's Business Daily

NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗

August 19, 2024

SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk ↗

August 16, 2024

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.